The FDA is considering pulling Pfizer’s (PFE) authorization to sell its Covid vaccine for children under the age of 5, Bloomberg’s Damian Garde reports. Pfizer has requested the authorization remain as it is through the coming fall season and is “currently in discussions with the agency on potential paths forward,” the company said. Pfizer’s vaccine remains approved for children over 5, and the company expects it to win full approval in that age group before Covid season hits in the fall, according to a person familiar with the matter. Moderna’s (MRNA) competing vaccine is approved for children under 12 who are at increased risk of the disease due to one or more underlying conditions, the report notes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer, Astellas Pharma announce topline results from EV-303 clinical trial
- Merck announces topline results from KEYNOTE-905 trial
- Pfizer’s New Study on Zavicefta: A Potential Game-Changer for Sepsis and Renal Impairment
- Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: Key Update for Investors
- Trump Considers Cannabis Reclassification That Could Boost $45 Billion U.S. Market